Bridge Therapeutics

Bridge Therapeutics

Comments

Bridge Therapeutics Names David H. Bergstrom, Ph.D. as Chief Executive Officer
https://tinyurl.com/4xz6wv6w
Buprenorphine Shown Safer Than Oxycodone for Relieving Chronic Pain in Recreational Opioid Users

https://tinyurl.com/fyjhyva6
“As clinicians and advocates on the frontlines of the addiction and overdose crisis, we call on congressional leaders to confront this epidemic with the urgency and boldness it requires,” the addiction specialty groups wrote to congress.
https://tinyurl.com/ye349yve
HHS Expands MAT Patient Access to Care, Cuts Prescribing Hurdles
“The medical evidence is clear: access to medication-assisted treatment, including buprenorphine that can be prescribed in office-based settings, is the gold standard for treating individuals suffering from opioid use disorder,” Adm. Brett P. Giroir, MD
tinyurl.com/4ihzfxt2
“Companies with limited R&D resources can forgo costly and more risky discovery and development of new chemical entities and instead make incremental innovations to existing drugs." - Dr. Babul https://tinyurl.com/yxakt3t9
Bridge Therapeutics has officially opened its first IND (Investigational New Drug) application with the FDA! https://www.bridgetherapeutics.com/press-releases/investigational-new-drug-ind-application-now-open-bt-219-opioid-dependence/
Bridge Therapeutics has submitted an IND application to the FDA for its lead product candidate BT-219. This is a major step in the development of an additional opioid addiction medication to combat the #opioidcrisis
See our press release:
https://tinyurl.com/INDPressRelease
https://www.newswire.com/news/bridge-therapeutics-announces-it-will-seek-fda-approval-for-bt-219-a-21030222
Bridge Therapeutics is pleased to announce it has received FDA feedback on the development of BT-219, a therapy to treat Opioid Dependence.
#OpioidEpidemic

Bridge Therapeutics® is an innovative development-stage specialty pharmaceutical company.

Operating as usual

Drug Development Company Bridge Therapeutics, Names David H. Bergstrom, Ph.D. as Chief Executive Officer | Bridge Therapeutics 07/26/2021

Drug Development Company Bridge Therapeutics, Names David H. Bergstrom, Ph.D. as Chief Executive Officer | Bridge Therapeutics

Bridge Therapeutics Names David H. Bergstrom, Ph.D. as Chief Executive Officer
https://tinyurl.com/4xz6wv6w

Drug Development Company Bridge Therapeutics, Names David H. Bergstrom, Ph.D. as Chief Executive Officer | Bridge Therapeutics Birmingham, AL – July 19 2021 – Bridge Therapeutics Inc. (Bridge) has promoted David H. Bergstrom, Ph.D. to the position of interim Chief Executive Officer. Dr. Bergstrom has more than 30 years of new product development and commercialization experience in the pharmaceutical industry. He has ove...

Buprenorphine Shown Safer Than Oxycodone for Relieving Chronic Pain in Recreational Opioid Users 05/19/2021

Buprenorphine Shown Safer Than Oxycodone for Relieving Chronic Pain in Recreational Opioid Users

Buprenorphine Shown Safer Than Oxycodone for Relieving Chronic Pain in Recreational Opioid Users

https://tinyurl.com/fyjhyva6

Buprenorphine Shown Safer Than Oxycodone for Relieving Chronic Pain in Recreational Opioid Users Buprenorphine buccal film may be a safer treatment option than oxycodone among recreational opioid users seeking treatment for chronic pain conditions, an analysis of a phase I trial has found.

Opioid Deaths Spark Push to Ease Buprenorphine Rules | Bridge Therapeutics 03/01/2021

Opioid Deaths Spark Push to Ease Buprenorphine Rules | Bridge Therapeutics

“As clinicians and advocates on the frontlines of the addiction and overdose crisis, we call on congressional leaders to confront this epidemic with the urgency and boldness it requires,” the addiction specialty groups wrote to congress.
https://tinyurl.com/ye349yve

Opioid Deaths Spark Push to Ease Buprenorphine Rules | Bridge Therapeutics In a Jan. 26 statement, the American Society of Addiction Medicine, the National Council for Behavioral Health and a handful of other addiction advocacy groups urged Congress to eliminate the training requirement as quickly as possible. “As clinicians and advocates on the frontlines of the addicti...

HHS Expands MAT Patient Access to Care, Cuts Prescribing Hurdles | Bridge Therapeutics 02/01/2021

HHS Expands MAT Patient Access to Care, Cuts Prescribing Hurdles | Bridge Therapeutics

HHS Expands MAT Patient Access to Care, Cuts Prescribing Hurdles
“The medical evidence is clear: access to medication-assisted treatment, including buprenorphine that can be prescribed in office-based settings, is the gold standard for treating individuals suffering from opioid use disorder,” Adm. Brett P. Giroir, MD
tinyurl.com/4ihzfxt2

HHS Expands MAT Patient Access to Care, Cuts Prescribing Hurdles | Bridge Therapeutics The Department of Health & Human Services has issued guidance to do away with the so-called X-waiver, a move the agency said will increase the number of providers able to deliver medication-assisted treatment and therefore increase patient access to care. “The medical evidence is clear: access to ...

Najib Babul Discusses the Benefits and Limitations of the 505(B)(2) Regulatory Pathway For Drug Approval | Bridge Therapeutics 01/19/2021

Najib Babul Discusses the Benefits and Limitations of the 505(B)(2) Regulatory Pathway For Drug Approval | Bridge Therapeutics

“Companies with limited R&D resources can forgo costly and more risky discovery and development of new chemical entities and instead make incremental innovations to existing drugs." - Dr. Babul https://tinyurl.com/yxakt3t9

Najib Babul Discusses the Benefits and Limitations of the 505(B)(2) Regulatory Pathway For Drug Approval | Bridge Therapeutics “Companies with limited R&D resources can forgo costly and more risky discovery and development of new chemical entities and instead make incremental innovations to existing drugs. In this manner, companies can use the 505(b)(2) regulatory pathway to repurpose or reposition drugs for new indicatio...

bridgetherapeutics.com 05/12/2020

Investigational New Drug (IND) Application Now Open for BT-219 for Opioid Dependence | Bridge Therapeutics

Bridge Therapeutics has officially opened its first IND (Investigational New Drug) application with the FDA! https://www.bridgetherapeutics.com/press-releases/investigational-new-drug-ind-application-now-open-bt-219-opioid-dependence/

bridgetherapeutics.com Birmingham, AL – April 27, 2020 – Bridge Therapeutics Inc. heard today from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application No.142396 for the Company’s lead product candidate, BT-219 (Bunalz™) is “Open and Safe to Proceed”. There were no ad...

bridgetherapeutics.com 03/31/2020

Bridge Therapeutics Submits Investigational New Drug (IND) Application for Lead Product Candidate BT-219 for Opioid Dependence | Bridge Therapeutics

Bridge Therapeutics has submitted an IND application to the FDA for its lead product candidate BT-219. This is a major step in the development of an additional opioid addiction medication to combat the #opioidcrisis
See our press release:
https://tinyurl.com/INDPressRelease

bridgetherapeutics.com Birmingham, AL – March 25, 2020 – Bridge Therapeutics Inc. today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the Company’s lead product candidate, BT-219 (Bunalz™). BT-219, or Bunalz™, is an investigationa...

bridgetherapeutics.com 02/25/2020

Bridge Therapeutics Demonstrates Formulation Stability of its Opioid Addiction Treatment | Bridge Therapeutics

https://www.bridgetherapeutics.com/press-releases/bridge-therapeutics-demonstrates-formulation-stability-opioid-addiction-treatment/

bridgetherapeutics.com Recently, analytical assessment of the 1-month stability of Bridge’s BT-219 therapy was completed with satisfactory results. Bridge’s Chief Operating Officer, David H Bergstrom, PhD, commented, “This is a significant milestone in that it demonstrates acceptable product characteristics and thus...

newswire.com 11/12/2019

Bridge Therapeutics Announces It Will Seek FDA Approval for BT-219, a Treatment for Opioid Dependence in the Coming Months

https://www.newswire.com/news/bridge-therapeutics-announces-it-will-seek-fda-approval-for-bt-219-a-21030222
Bridge Therapeutics is pleased to announce it has received FDA feedback on the development of BT-219, a therapy to treat Opioid Dependence.
#OpioidEpidemic

newswire.com Bridge Therapeutics Announces It Will Seek FDA Approval for BT-219, a Treatment for Opioid Dependence in the Coming Months Press Release - updated: Nov 7, 2019 BIRMINGHAM, Ala., November 7, 2019 (Newswire.com) - ​Bridge Therapeutics Inc. today announced that it has received feedback from the Food ...

newswire.com 04/23/2019

Bridge Therapeutics Announces the Addition of Edward J. Minskoff to Its Board of Directors

https://www.newswire.com/news/bridge-therapeutics-announces-the-addition-of-edward-j-minskoff-to-its-20870736
Bridge Therapeutics is pleased to announce the addition of Edward Minskoff to our Board of Directors!

newswire.com Bridge Therapeutics Announces the Addition of Edward J. Minskoff to Its Board of Directors Press Release - updated: Apr 23, 2019 09:26 CDT BIRMINGHAM, Ala., April 23, 2019 (Newswire.com) - ​Bridge Therapeutics, an innovative startup pharmaceutical company developing a practical and safe therapy fo...

02/01/2019

Medical Leaders: Elevate Evidence Over Bias in Opioid Disorder Treatment | Behavioral Healthcare Executive

The evidence for using buprenorphine in the treatment of opioid addiction is overwhelming, yet stigmas and biases still remain leading to inadequate treatment of those battling addiction.

behavioral.net December 21, 2018 by Gary A. Enos, Contributing Editor | Reprints An editorial co-authored by experts at Boston Medical Center and published this week in a primary care journal takes aim at restrictive government regulations and lingering provider biases that hinder access to two of the three approv...

psychcongress.com 12/19/2018

Buprenorphine-Naloxone Advised Over Extended-Release Naltrexone for Opioid Use Disorder | Psych Congress

psychcongress.com Buprenorphine-naloxone should be favored over extended-release naltrexone as first-line treatment for opioid use disorder (OUD) in adults, according to a cost-effectiveness analysis.

newswire.com 11/08/2018

Dr. Steven Passik Has Joined the Scientific Advisory Board of Bridge Therapeutics

Steve Passik Ph.D., a recognized leader and researcher in pain management and addiction joins Bridge Therapeutics’ Scientific Advisory Board.

newswire.com Bridge Therapeutics Announces the Addition of Dr. Steve Passik to Its Scientific Advisory Board

11/05/2018

Bridge Therapeutics Announces the Addition of Dr. Bob Rappaport to Its Scientific Advisory Board

As their newest member, Dr. Bob Rappaport brings decades of drug approval experience to Bridge Therapeutics' Scientific Advisory Board.

newswire.com Dr. Bob Rappaport joins Bridge Therapeutics' Scientific Advisory Board as its newest member

aafp.org 10/19/2018

Panel: Buprenorphine 'Can Give Patients Their Lives Back'

David O'Gurek, M.D., said stigma is one of the challenges of overcoming substance abuse disorder. He said buprenorphine can help by giving people more control.

aafp.org During a Family Medicine Experience main-stage presentation on opioids, an HHS representative said family physicians can help curb the crisis by prescribing buprenorphine. A panel of family physicians agreed.

prnewswire.com 10/02/2018

Dr. Bob Raffa Joins Bridge Therapeutics' Scientific Advisory Board Bring Decades of Research and Experience

Bridge Therapeutics announces the addition of Dr. Bob Raffa as its newest Scientific Advisory Board member.

prnewswire.com BIRMINGHAM, Ala., Sept. 21, 2018 /PRNewswire/ -- Pharmaceutical startup Bridge Therapeutics announces the addition of Dr. Bob Raffa as its newest Scientific...

09/13/2018
09/04/2018
newswire.com 08/29/2018

Dr. Jeffrey Fudin, a Leading Pain Researcher, Joins Bridge Therapeutics Advisory Board

Bridge Therapeutics is happy to announce the addition of Dr. Jeffrey Fudin to its Scientific Advisory Board. Among other activities and accolades, Dr. Fudin is an active lecturer, writer, and researcher on pain management issues.

newswire.com

nbcnews.com 08/23/2018

This opioid addiction treatment helped France combat its own epidemic

Unlike the US, France allows all physicians to prescribe Buprenorphine to treat opioid addiction. Reducing the barriers in the US would allow for more patients to recover using this proven lifesaving treatment.

nbcnews.com Buprenorphine is a treatment for opioid addiction designed to curb cravings and reduce overdoses. France changed the law in the 1990s to allow all practitioners to prescribe it and the cost is covered under the country’s universal health care.

painmedicinenews.com 08/21/2018

Medication-Assisted Treatments Underused in Patients With Opioid Use Disorder

According to an NIH study, adults prescribed Buprenorphine had a decreased mortality rate of 38%, compared with patients not receiving any medication-assisted treatment over the one-year study period.

painmedicinenews.com Treatment of opioid use disorder after a nonfatal opioid overdose with either methadone or buprenorphine is underutilized when compared with each therapy’s proven ability to dramatically reduce mortality rates, according to a study in the Annals of Internal Medicine (2018 Jun 19. [Epu...

washingtonexaminer.com 08/17/2018

To fight the opioid crisis, the US needs to look at what works

In this article, The Washington Examiner discusses the effectiveness of Buprenorphine for treating opioid addiction as well as the red tape that's limiting access to the life saving therapy.

washingtonexaminer.com The Center for Disease Control and Prevention released preliminary overdose estimates for 2017. Although a few states offer some encouraging examples of progress, the estimates — or even just one, the record 72,000 overdose deaths — offer a troubling look at how the United States is still…

07/30/2018
nejm.org 07/24/2018

Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities | NEJM

In a recent New England Journal of Medicine article, addiction experts Sarah Wakeman MD and Michael Barnett MD, discuss how “to have any hope of stemming the overdose tide, we have to make it easier to obtain buprenorphine than to get he**in and fentanyl.”

nejm.org Perspective from The New England Journal of Medicine — Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities

pbs.org 07/20/2018

How a brain gets hooked on opioids

In this article by PBS explains how traditional opioids interact with the receptors in the brain to produce analgesia (pain relief), constipation, depression, and euphoria.

pbs.org Here is the neuroscience behind how opioids overtake the human brain.

bridgetherapeutics.com 07/19/2018

Opioid addiction is keeping a high percentage of people out of the workforce, Fed chairman says | Bridge Therapeutics

"The opioid crisis gripping communities across the U.S. also is taking an economic toll, Fed Chairman Jerome Powell said.”

bridgetherapeutics.com America’s opioid epidemic is exacting a massive human toll that also is impacting the economy, Federal Reserve Chairman Jerome Powell said Tuesday. “From an economic standpoint, some high percentage of prime-age people who are not in the labor force, particularly prime-age males who are not in t...

newswire.com 07/09/2018

Pharma Startup, Bridge Therapeutics, Will Unveil Its Chronic Pain Drug Development Program at the 2018 youngStartup Ventures Summit in New York

After a great holiday week, the Bridge Team is gearing up for a series of trips and events as we prepare to release our Chronic Pain Drug Development Program. Please share our page with your family and friends & take a look at our website as we work towards practical solution in ending the Opioid Crisis!

newswire.com Pharma Startup, Bridge Therapeutics, Will Unveil Its Chronic Pain Drug Development Program at the 2018 youngStartup Ventures Summit in New York Press Release - updated: Jul 9, 2018 11:07 EDT NEW YORK, July 9, 2018 (Newswire.com) - Executives with the innovative late development-stage pharmaceutical....

06/12/2018

The Bridge Therapeutics Team traveled to Boston for the BIO International Convention. Bridge met with investors as well as worked to attain other sources of capital. The team, also, met with vendors and service providers in preparation for the launch of their lead investigational drug BT-205. Bridge’s Tim Peara, Alton Kelley, and Dave Bergstrom were a part of the nearly 47,000 partnering meetings that occurred making them a part of the Guinness Book of World Records “Largest Business Partnering Event”.

“We’re really hoping to work with investors on financing so we can get our drug to the FDA,” said Alton Kelley, the firm’s director of business development. “We’re going to need a little more capital to get it through the finish line.

http://www.biotech-now.org/events/2018/06/bio2018-makes-history-in-boston

06/05/2018

According to the National Institute on Drug Abuse, more than 17,000 people overdosed while using prescription opioids in 2016.

#NationalInstituteonDrugAbuse #OpioidCrisis #TheMoreYoKnow #BridgeTherapeutics #Addiction #DrugAbuse

05/30/2018

While U.S. Citizen only make up 5% of the world's population, the U.S. consumes roughly 80% of the world's prescription opioid drugs.

#NationalInstituteonDrugAbuse #OpioidCrisis #TheMoreYoKnow #BridgeTherapeutics #Addiction #DrugAbuse

05/24/2018

According to the National Institute on Drug Abuse, 80% of He**in Addicts started by abusing pain medication.

05/24/2018

Bridge Therapeutics's cover photo

newswire.com 05/21/2018

Pharmaceutical Startup Bridge Therapeutics Announces New Headquarters in Birmingham, Alabama

Bridge Therapeutics is an innovative development-stage specialty pharmaceutical company that is actively researching chronic pain alternatives to help reduce the impact of the opioid epidemic. The pharma company is currently pursuing FDA and European Medicines Agency (EMA) approval of a patented drug combination for the treatment of chronic pain in opioid-experienced patients.

newswire.com Pharmaceutical Startup Bridge Therapeutics Announces New Headquarters in Birmingham, Alabama Press Release - updated: May 16, 2018 BIRMINGHAM, Ala., May 16, 2018 (Newswire.com) - ​​The innovative late development-stage pharmaceutical startup Bridge Therapeutics has announced they will be expandi...

05/21/2018

Bridge Therapeutics

About Us

Bridge Therapeutics, Inc. is a development-stage biotech company pursuing FDA approval of a patented drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients.

OUR MISSION

Our goal is to improve lives of patients living with chronic pain by developing new approaches to pain management that are safer, more effective, and non-addictive.

Telephone

Address


240 Summit Blvd Suite 202
Birmingham, AL
35243

Opening Hours

Monday 8am - 4pm
5pm - 6pm
Tuesday 8am - 4pm
Wednesday 8am - 4pm
Thursday 8am - 4pm
Friday 8am - 4pm
Other Medical & Health in Birmingham (show all)
Irene's Health Talk Show Irene's Health Talk Show
Birmingham, 35203

Breast Cancer Research Foundation of Alabama Breast Cancer Research Foundation of Alabama
1802 6th Avenue South
Birmingham, 35294

Our mission is to help find a cure for breast cancer by investing in promising research across Alabama and to raise community awareness and funding for that research. Since 1996, we've invested over $11 million in breast cancer research across the state.

Revamped Beauty Revamped Beauty
2714 5 Pts W Ensley Ave
Birmingham, 35218

A 501c3 public charity that helps men and women live their most beautiful lives in the face of a breast cancer dx by providing access to specialized medical equipment, beauty supplies, and personal care items.

Veritas Medical Real Estate Advisors Veritas Medical Real Estate Advisors
2730 19th Street South
Birmingham, 35209

Our mission at Veritas Medical Real Estate is to provide exceptional real estate advisory services to physicians and medical groups based on the core principles of truth, integrity and hard work. We focus on assisting medical practices in making informed

Natural Rug Care Natural Rug Care
Birmingham, 35242

UAB Spinal Cord Injury Model System (UAB-SCIMS) UAB Spinal Cord Injury Model System (UAB-SCIMS)
1717 6th Ave S
Birmingham, 35233

The University of Alabama at Birmingham Spinal Cord Injury Model System is one of 14 national SCI Model Systems programs in the US.

Just like family home health care -JLF Just like family home health care -JLF
Birmingham

JLF is a non medical health care business we work hard to accommodate our client and family with their every day living

Samford University McWhorter School of Pharmacy Samford University McWhorter School of Pharmacy
800 Lakeshore Dr
Birmingham, 35229

This is the official Facebook account for Samford University's McWhorter School of Pharmacy.

Alabama Vision Coalition Alabama Vision Coalition
700 South 18th St
Birmingham, 35233

The Alabama Vision Coalition supports access to vision care, education, and research in Alabama

Southern Med Law Southern Med Law
2224 1st Ave. North
Birmingham, 35209

Southern Med Law provides legal representation to victims of harmful drugs, defective medical devices, dangerous products, and other legal claims.

Mirena Pregnancy/Birth Defects Lawsuit Information Mirena Pregnancy/Birth Defects Lawsuit Information
Birmingham, 35209

Dr. Blaudeau's first-hand knowledge of Mirena IUD birth defects makes him a powerful legal advocate for women who suffered side effects from Mirena IUDs.